Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autolus Therapeutics PLC
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Liabilities
$263.9m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Liabilities
$124m
CAGR 3-Years
143%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Liabilities
ÂŁ155m
CAGR 3-Years
81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Liabilities
$165.7m
CAGR 3-Years
14%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Liabilities
ÂŁ228.2m
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Liabilities
ÂŁ480.7m
CAGR 3-Years
11%
CAGR 5-Years
9%
CAGR 10-Years
5%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Total Liabilities?
Total Liabilities
263.9m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Total Liabilities amounts to 263.9m USD.

What is Autolus Therapeutics PLC's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
46%

Over the last year, the Total Liabilities growth was 38%. The average annual Total Liabilities growth rates for Autolus Therapeutics PLC have been 46% over the past three years .

Back to Top